Bio-Path控股

BPTH NASDAQ
13.72
-0.15
-1.08%
盘后: 13.89 +0.17 +1.24% 17:58 07/19 EDT
开盘
13.73
昨收
13.87
最高
13.78
最低
13.25
成交量
14.20万
成交均量(3M)
21.20万
52周最高
73.52
52周最低
1.610
换手率
5.01%
市值
3,884.62万
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Bio-Path控股 BPTH股票价格,Bio-Path控股股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification. Its lead drug candidate, Liposomal Grb2 (BP1001), targets the protein Growth factor receptor-bound protein 2 (Grb2). Its other liposome delivered antisense drug candidate, Liposomal Bcl2 (BP1002), targets the protein B-cell lymphoma 2 (Bcl2). BP1001 is in Phase II clinical trials for acute myeloid leukemia, and for blast phase and accelerated phase chronic myelogenous leukemia. BP1002 is intended to target the lymphoma and certain solid tumor markets. BP1001 is also in preclinical studies for solid tumors, including triple negative breast cancer and inflammatory breast cancer.
展开 >

最近浏览

名称
价格
涨跌幅